146 related articles for article (PubMed ID: 20098785)
1. [Antifungal effect of high molecular weight chitosan on Candida spp isolated from clinical samples].
Tapia CP; Soto DM; Vergara LG; Alburquerque CO; Maccioni AR; Matamata AM; Hermosilla GD; Bucarey SV
Rev Chilena Infectol; 2009 Dec; 26(6):515-9. PubMed ID: 20098785
[TBL] [Abstract][Full Text] [Related]
2. Antifungal effect of high- and low-molecular-weight chitosan hydrochloride, carboxymethyl chitosan, chitosan oligosaccharide and N-acetyl-D-glucosamine against Candida albicans, Candida krusei and Candida glabrata.
Seyfarth F; Schliemann S; Elsner P; Hipler UC
Int J Pharm; 2008 Apr; 353(1-2):139-48. PubMed ID: 18164151
[TBL] [Abstract][Full Text] [Related]
3. Antifungal activity of low molecular weight chitosan against clinical isolates of Candida spp.
Alburquenque C; Bucarey SA; Neira-Carrillo A; Urzúa B; Hermosilla G; Tapia CV
Med Mycol; 2010 Dec; 48(8):1018-23. PubMed ID: 20482450
[TBL] [Abstract][Full Text] [Related]
4. [CHROMAgar Candida with fluconazole: comparison with microdilution techniques].
Linares MJ; Charriel G; Solís F; Casal M
Enferm Infecc Microbiol Clin; 2003 Nov; 21(9):493-7. PubMed ID: 14572382
[TBL] [Abstract][Full Text] [Related]
5. In vitro susceptibility of Candida species to five antifungal agents in a German university hospital assessed by the reference broth microdilution method and Etest.
Fleck R; Dietz A; Hof H
J Antimicrob Chemother; 2007 Apr; 59(4):767-71. PubMed ID: 17293369
[TBL] [Abstract][Full Text] [Related]
6. [Antifungal susceptibility of Candida spp. isolates from blood cultures in a five-year period (1997-2001)].
Durán MT; Velasco D; Canle D; Moure R; Villanueva R
Enferm Infecc Microbiol Clin; 2003 Nov; 21(9):488-92. PubMed ID: 14572381
[TBL] [Abstract][Full Text] [Related]
7. In vitro anticandidal activity of xanthorrhizol isolated from Curcuma xanthorrhiza Roxb.
Rukayadi Y; Yong D; Hwang JK
J Antimicrob Chemother; 2006 Jun; 57(6):1231-4. PubMed ID: 16617064
[TBL] [Abstract][Full Text] [Related]
8. Anti-Candida activity of a chitosan hydrogel: mechanism of action and cytotoxicity profile.
Palmeira-de-Oliveira A; Ribeiro MP; Palmeira-de-Oliveira R; Gaspar C; Costa-de-Oliveira S; Correia IJ; Pina Vaz C; Martinez-de-Oliveira J; Queiroz JA; Rodrigues AG
Gynecol Obstet Invest; 2010; 70(4):322-7. PubMed ID: 21109742
[TBL] [Abstract][Full Text] [Related]
9. Non-albicans Candida spp. causing fungaemia: pathogenicity and antifungal resistance.
Krcmery V; Barnes AJ
J Hosp Infect; 2002 Apr; 50(4):243-60. PubMed ID: 12014897
[TBL] [Abstract][Full Text] [Related]
10. Antifungal susceptibility of Candida spp. isolated from pediatric patients: a survey of 4 children's hospitals.
Zaoutis TE; Foraker E; McGowan KL; Mortensen J; Campos J; Walsh TJ; Klein JD
Diagn Microbiol Infect Dis; 2005 Aug; 52(4):295-8. PubMed ID: 15922535
[TBL] [Abstract][Full Text] [Related]
11. Mycological and electron microscopic study of Solanum chrysotrichum saponin SC-2 antifungal activity on Candida species of medical significance.
Herrera-Arellano A; Martínez-Rivera Mde L; Hernández-Cruz M; López-Villegas EO; Rodríguez-Tovar AV; Alvarez L; Marquina-Bahena S; Navarro-García VM; Tortoriello J
Planta Med; 2007 Dec; 73(15):1568-73. PubMed ID: 18058612
[TBL] [Abstract][Full Text] [Related]
12. [Species distribution and fluconazole susceptibility of yeasts of genus Candida isolated from hospitalized and ambulatory patients].
Alburquerque C; Hermosilla G; Tapia C
Rev Chilena Infectol; 2009 Oct; 26(5):435-9. PubMed ID: 19915753
[TBL] [Abstract][Full Text] [Related]
13. National surveillance of species distribution in blood isolates of Candida species in Japan and their susceptibility to six antifungal agents including voriconazole and micafungin.
Takakura S; Fujihara N; Saito T; Kudo T; Iinuma Y; Ichiyama S
J Antimicrob Chemother; 2004 Feb; 53(2):283-9. PubMed ID: 14688039
[TBL] [Abstract][Full Text] [Related]
14. Antifungal resistance in Candida spp. isolated in Italy between 2002 and 2005 from children and adults.
Gualco L; Debbia EA; Bandettini R; Pescetto L; Cavallero A; Ossi MC; Schito AM; Marchese A
Int J Antimicrob Agents; 2007 Feb; 29(2):179-84. PubMed ID: 17175140
[TBL] [Abstract][Full Text] [Related]
15. [Vaginal candidiasis: etiology and sensitivity profile to antifungal agents in clinical use].
Saporiti AM; Gómez D; Levalle S; Galeano M; Davel G; Vivot W; Rodero L
Rev Argent Microbiol; 2001; 33(4):217-22. PubMed ID: 11833253
[TBL] [Abstract][Full Text] [Related]
16. [Investigation of the activity of the preparation cerbiden against Candida spp].
Hladun NP; Bondarenko AS; Nahorna SS; Smyrnova OV
Mikrobiol Z; 2002; 64(6):57-61. PubMed ID: 12664551
[TBL] [Abstract][Full Text] [Related]
17. Survey of amphotericin B susceptibility of Candida clinical isolates determined by Etest.
Chiu YS; Chang SC; Hsueh PR; Wang JL; Sun HY; Chen YC
J Microbiol Immunol Infect; 2006 Aug; 39(4):335-41. PubMed ID: 16926981
[TBL] [Abstract][Full Text] [Related]
18. In vitro susceptibility testing of Candida and Aspergillus spp. to voriconazole and other antifungal agents using Etest: results of a French multicentre study.
Mallié M; Bastide JM; Blancard A; Bonnin A; Bretagne S; Cambon M; Chandenier J; Chauveau V; Couprie B; Datry A; Feuilhade M; Grillot R; Guiguen C; Lavarde V; Letscher V; Linas MD; Michel A; Morin O; Paugam A; Piens MA; Raberin H; Tissot E; Toubas D; Wade A
Int J Antimicrob Agents; 2005 Apr; 25(4):321-8. PubMed ID: 15784312
[TBL] [Abstract][Full Text] [Related]
19. [Susceptibility to miconazole and itraconazole of Candida strains isolated from hospitalized and outpatient clinic patients].
Kurnatowska AK; Kwaśniewska J
Wiad Parazytol; 2009; 55(4):415-23. PubMed ID: 20209818
[TBL] [Abstract][Full Text] [Related]
20. In vitro antifungal activity of phenylheptatriyne from Bidens cernua L. against yeasts.
Rybalchenko NP; Prykhodko VA; Nagorna SS; Volynets NN; Ostapchuk AN; Klochko VV; Rybalchenko TV; Avdeeva LV
Fitoterapia; 2010 Jul; 81(5):336-8. PubMed ID: 19837144
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
